BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026

Rhea-AI Summary

BridgeBio (NASDAQ: BBIO) announced presentations of new Phase 3 ATTRibute-CM data for acoramidis at ESC-Heart Failure 2026 in Barcelona on May 9–12, 2026.

Highlights include a late-breaking oral presentation by Bayer on outpatient worsening heart failure, data on NT-proBNP at Month 30, and KCCQ-OS quality-of-life results.

Positive

• Late-breaking oral presentation on acoramidis’ effect on outpatient worsening heart failure
• Phase 3 ATTRibute-CM data include NT-proBNP reduction to Month 30 versus placebo
• Consistent KCCQ-OS quality-of-life benefit with acoramidis across subgroups
• Acoramidis is approved in the US, EU, Japan, UK, and Switzerland
• Bayer presenting as exclusive European licensing partner

Negative

• None.

News Market Reaction – BBIO

+0.63%

1 alert

+0.63% News Effect

On the day this news was published, BBIO gained 0.63%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Trial phase: Phase 3 Conference dates: May 9–12, 2026 Late-breaker time: May 11, 3:30 pm CEST +5 more

8 metrics

Trial phase Phase 3 ATTRibute-CM study for transthyretin amyloid cardiomyopathy (ATTR-CM)

Conference dates May 9–12, 2026 Heart Failure 2026 (ESC-HF) meeting in Barcelona

Late-breaker time May 11, 3:30 pm CEST Late-breaking oral presentation on temporal variability of serum transthyretin

ePoster time May 10, 3:30 pm CEST Anchored matching-adjusted indirect comparison vs tafamidis ePoster

NT-proBNP horizon Month 30 Acoramidis effect on NT-proBNP rise from baseline to Month 30

KCCQ-OS time May 9, 12:56 pm CEST Poster on KCCQ-OS benefits across subgroups in ATTRibute-CM

Health status poster May 9, 3:36 pm CEST Poster on maintenance/improvement of heart failure-related health status

Regulatory approvals Multiple regions Acoramidis approved in U.S., EU, Japan, Switzerland, and UK labels

Market Reality Check

Price: $68.08 Vol: Volume 1,790,339 is below...

normal vol

$68.08 Last Close

Volume Volume 1,790,339 is below 20-day average 2,530,064 (relative volume 0.71) ahead of the data presentations. normal

Technical Price 68.56 is trading above 200-day MA of 64.39, despite a -3.59% move over the last 24 hours.

Peers on Argus

BBIO fell -3.59% while key biotech peers were mixed: BMRN (+0.33%), IONS (+0.56%...

BBIO fell -3.59% while key biotech peers were mixed: BMRN (+0.33%), IONS (+0.56%), SMMT (+0.59%) up, EXEL (-0.73%) and ASND (-3.68%) down, indicating stock-specific dynamics rather than a broad sector move.

Historical Context

5 past events · Latest: Apr 30 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Apr 30	Earnings scheduling	Neutral	+0.2%	Announcement of timing for Q1 2026 results and commercial updates.
Apr 28	Awareness campaign	Positive	-6.5%	Launch of national ATTR-CM health education effort featuring high-profile advocates.
Apr 22	Equity inducement grants	Negative	-2.2%	Inducement RSU grants to new employees under existing equity plan.
Mar 30	Clinical outcomes data	Positive	-0.5%	Long-term acoramidis data showing reduced all-cause and cardiovascular mortality.
Mar 30	Regulatory filing	Positive	-0.5%	Submission of NDA for BBP-418 in LGMD2I/R9 supported by positive Phase 3 data.

Pattern Detected

Recent clinically positive and strategic announcements have often coincided with flat to negative next-day moves, suggesting the stock has not consistently risen on favorable pipeline or commercial updates.

Recent Company History

Over the last several months, BridgeBio has issued a mix of commercial, pipeline, and corporate updates. These include scheduling of Q1 2026 results, a national ATTR-CM education campaign, equity inducement grants, long-term acoramidis mortality data through Month 54, and submission of an NDA for BBP-418 in LGMD2I/R9. Despite multiple positive clinical and regulatory milestones, 24-hour price reactions were often modestly negative, framing today’s new acoramidis data presentations within a pattern where strong fundamentals have not always translated into immediate upside.

Market Pulse Summary

This announcement highlights upcoming detailed acoramidis data from the Phase 3 ATTRibute-CM study a...

Analysis

This announcement highlights upcoming detailed acoramidis data from the Phase 3 ATTRibute-CM study at ESC-Heart Failure 2026, including outcomes, biomarkers like NT-proBNP, and patient-reported KCCQ-OS measures. It follows previously reported mortality benefits through Month 54 and existing approvals across the U.S., EU, Japan, Switzerland, and the UK. Investors may track how these analyses refine understanding of disease progression, compare indirectly with tafamidis, and connect with prior regulatory milestones and commercial updates in ATTR-CM.

Key Terms

phase 3, transthyretin amyloid cardiomyopathy, nt-probnp, kansas city cardiomyopathy questionnaire, +4 more

8 terms

phase 3 medical

"new data from the Phase 3 ATTRibute-CM study in individuals"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

transthyretin amyloid cardiomyopathy medical

"study in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM)"

Transthyretin amyloid cardiomyopathy is a progressive heart condition where a normally circulating protein, transthyretin, misfolds and forms sticky clumps that build up in the heart, making it stiff and less able to pump. For investors, it matters because diagnosing and treating this disease drives demand for specialized drugs, tests and long-term care, creating a distinct market opportunity tied to regulatory approvals, pricing and reimbursement decisions.

nt-probnp medical

"Acoramidis Treatment Attenuates the Rise in NT-proBNP from Baseline"

A blood test marker released when the heart is under strain; higher NT‑proBNP levels indicate the heart is working harder or may be failing, similar to a dashboard warning light that signals engine stress. Investors watch NT‑proBNP because changes in the marker can drive clinical trial results, treatment approvals, hospital use, and insurance decisions for heart drugs and devices, all of which affect revenue, adoption and valuation in healthcare companies.

kansas city cardiomyopathy questionnaire medical

"Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS)"

A patient questionnaire that measures symptoms, physical limitations and quality of life for people with heart failure; it gives a standardized score that reflects how the condition affects daily living. Investors care because the score is often used as a clinical-trial endpoint or regulatory evidence to show a treatment actually improves patients’ lives, similar to a customer-satisfaction rating that can influence approval, reimbursement and market uptake.

kccq-os medical

"Questionnaire Overall Summary Score (KCCQ-OS) with Acoramidis Treatment"

A KCCQ-OS is the overall summary score from the Kansas City Cardiomyopathy Questionnaire, a patient-reported survey that quantifies how heart failure affects a person’s symptoms, physical ability, social limits and quality of life. For investors it acts like a customer satisfaction score for a therapy or device: higher KCCQ-OS values signal meaningful patient benefit, which can influence regulatory approval, guideline endorsements, market uptake and reimbursement decisions.

anchored matching-adjusted indirect comparison technical

"Anchored Matching-Adjusted Indirect Comparison of Acoramidis (ATTRibute-CM)"

An anchored matching-adjusted indirect comparison is a statistical method used to compare the effectiveness or safety of two treatments when they have not been tested directly against each other but have each been compared to a common standard. It works by reweighting patient-level data from one study so the groups look similar on key characteristics, like adjusting two sets of product reviews to match demographics of a shared reference review; investors pay attention because these analyses influence how regulators, payers and clinicians perceive a therapy’s value, which can affect market access, pricing and sales forecasts.

european medicines agency regulatory

"approved as BEYONTTRA® by the European Medicines Agency (EMA)"

The European Medicines Agency is the central drug regulator that evaluates and authorizes medicines for use across the European Union and related countries, similar to a referee or safety inspector who checks that a medicine is safe and effective before it can be sold. Its decisions matter to investors because approvals, rejections, or safety warnings directly affect a drug maker’s ability to sell products, generate revenue, and face legal or reputational risks, which in turn influence stock value.

medicines and healthcare products regulatory agency regulatory

"the UK Medicines and Healthcare Products Regulatory Agency with all labels"

A medicines and healthcare products regulatory agency is a government body that assesses, licenses and monitors the safety, effectiveness and quality of medicines, vaccines and medical devices before and after they reach the market. For investors, its decisions act like a building inspector’s approval — they determine whether a product can be sold, the timing and scope of market access, and can therefore quickly affect a company’s revenue prospects, costs and valuation.

AI-generated analysis. Not financial advice.

PALO ALTO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today upcoming presentations, including one late-breaking oral presentation, of new data from the Phase 3 ATTRibute-CM study in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) at Heart Failure 2026, organized by the Heart Failure Association of the European Society of Cardiology (ESC-HF), taking place in Barcelona, Spain on May 9-12, 2026.

Bayer, BridgeBio’s exclusive European licensing partner of acoramidis, will be presenting a late-breaking oral presentation on data from ATTRibute-CM related to acoramidis’ impact on the outcome of outpatient worsening heart failure.

Acoramidis is approved as Attruby^® by the U.S. FDA and is approved as BEYONTTRA^® by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the Swiss Agency for Therapeutic Products, and the UK Medicines and Healthcare Products Regulatory Agency with all labels specifying near-complete stabilization of TTR.

Late-Breaking Oral Presentation:
Effect of Acoramidis on Temporal Variability of Serum Transthyretin and its Influence on Outcomes: Insights from the ATTRibute-CM Trial
Presenter: Senthil Selvaraj, M.D., Duke University School of Medicine, U.S.
Date: Monday, May 11 at 3:30 pm CEST

Moderated ePoster:
Anchored Matching-Adjusted Indirect Comparison of Acoramidis (ATTRibute-CM) Versus Tafamidis (ATTR-ACT) for Risk of Cardiovascular-Related Hospitalization, All-Cause Mortality and Safety in ATTR-CM
Presenter: Emer Joyce, M.D., Ph.D., The Mater Misericordiae University Hospital, IE
Date: Sunday, May 10 at 3:30 pm CEST

Acoramidis Treatment Attenuates the Rise in NT-proBNP from Baseline to Month 30 Compared to Placebo Across all Subgroups
Presenter: Marianna Fontana, M.D., University College London, UK
Date: Monday, May 10 at 3:30 pm CEST

Posters:
Consistent Benefit on Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) with Acoramidis Treatment Compared with Placebo Across Participant Subgroups in ATTRibute-CM
Presenter: Marianna Fontana, M.D., University College London, UK
Date: Saturday, May 9 at 12:56 pm CEST

Effect of Acoramidis on Improvement or Maintenance of Heart Failure-Related Health Status as Assessed by KCCQ-OS Score in ATTRibute-CM
Presenter: Charles Sherrod, M.D., Saint Luke’s Health System, Kansas City, U.S.
Date: Saturday, May 9 at 3:36 pm CEST

About Attruby™ (acoramidis)

INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com   
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com 

FAQ

What new acoramidis data will BridgeBio (BBIO) present at ESC-Heart Failure 2026?

BridgeBio will present Phase 3 ATTRibute-CM data including NT-proBNP, KCCQ-OS, and hospitalization outcomes. According to BridgeBio, sessions include a late-breaking oral presentation on outpatient worsening heart failure and multiple moderated ePosters and posters May 9–11, 2026.

When and where is the late-breaking oral presentation on acoramidis at ESC-Heart Failure 2026?

The late-breaking oral presentation is scheduled for May 11, 2026 at 3:30 pm CEST in Barcelona. According to BridgeBio, Bayer will present late-breaking data on acoramidis’ impact on outpatient worsening heart failure.

What clinical endpoints from ATTRibute-CM are being reported for acoramidis at the conference?

Reported endpoints include temporal variability of serum transthyretin, NT-proBNP change to Month 30, KCCQ-OS quality-of-life scores, and hospitalization/mortality comparisons. According to BridgeBio, these results are drawn from the Phase 3 ATTRibute-CM dataset.

Does acoramidis have regulatory approvals relevant to investors and patients?

Yes. According to BridgeBio, acoramidis is approved as Attruby in the US and as BEYONTTRA in the EU, plus approvals in Japan, Switzerland, and the UK, with labels noting near-complete stabilization of transthyretin.

Who will present the comparative analysis of acoramidis versus tafamidis at ESC-Heart Failure 2026?

A moderated ePoster comparing acoramidis and tafamidis will be presented by Emer Joyce, M.D., Ph.D., on May 10, 2026 at 3:30 pm CEST. According to BridgeBio, it uses anchored matching-adjusted indirect comparison methods from ATTRibute-CM data.

How do the presented acoramidis quality-of-life results affect patients with ATTR-CM?

Presentations report consistent benefit on KCCQ-OS with acoramidis versus placebo across participant subgroups. According to BridgeBio, posters and talks will detail KCCQ-OS maintenance or improvement findings from the ATTRibute-CM trial.